AU2014230096C1 - Use of linagliptin in cardio- and renoprotective antidiabetic therapy - Google Patents

Use of linagliptin in cardio- and renoprotective antidiabetic therapy Download PDF

Info

Publication number
AU2014230096C1
AU2014230096C1 AU2014230096A AU2014230096A AU2014230096C1 AU 2014230096 C1 AU2014230096 C1 AU 2014230096C1 AU 2014230096 A AU2014230096 A AU 2014230096A AU 2014230096 A AU2014230096 A AU 2014230096A AU 2014230096 C1 AU2014230096 C1 AU 2014230096C1
Authority
AU
Australia
Prior art keywords
disease
renal
patient
risk
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014230096A
Other languages
English (en)
Other versions
AU2014230096A1 (en
AU2014230096B2 (en
Inventor
Odd-Erik JOHANSEN
Thomas Klein
Maximilian VON EYNATTEN
Hans-Juergen Woerle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50277246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014230096(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU2014230096A1 publication Critical patent/AU2014230096A1/en
Application granted granted Critical
Publication of AU2014230096B2 publication Critical patent/AU2014230096B2/en
Priority to AU2019203445A priority Critical patent/AU2019203445A1/en
Publication of AU2014230096C1 publication Critical patent/AU2014230096C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2014230096A 2013-03-15 2014-03-14 Use of linagliptin in cardio- and renoprotective antidiabetic therapy Active AU2014230096C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019203445A AU2019203445A1 (en) 2013-03-15 2019-05-16 Use of linagliptin in cardio- and renoprotective antidiabetic therapy

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13159624.9 2013-03-15
EP13159624 2013-03-15
EP13177311 2013-07-19
EP13177311.1 2013-07-19
PCT/EP2014/055113 WO2014140284A1 (en) 2013-03-15 2014-03-14 Use of linagliptin in cardio- and renoprotective antidiabetic therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019203445A Division AU2019203445A1 (en) 2013-03-15 2019-05-16 Use of linagliptin in cardio- and renoprotective antidiabetic therapy

Publications (3)

Publication Number Publication Date
AU2014230096A1 AU2014230096A1 (en) 2015-08-06
AU2014230096B2 AU2014230096B2 (en) 2019-02-21
AU2014230096C1 true AU2014230096C1 (en) 2019-08-29

Family

ID=50277246

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014230096A Active AU2014230096C1 (en) 2013-03-15 2014-03-14 Use of linagliptin in cardio- and renoprotective antidiabetic therapy
AU2019203445A Abandoned AU2019203445A1 (en) 2013-03-15 2019-05-16 Use of linagliptin in cardio- and renoprotective antidiabetic therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019203445A Abandoned AU2019203445A1 (en) 2013-03-15 2019-05-16 Use of linagliptin in cardio- and renoprotective antidiabetic therapy

Country Status (14)

Country Link
US (9) US20140274889A1 (cg-RX-API-DMAC7.html)
EP (4) EP4364796A3 (cg-RX-API-DMAC7.html)
JP (4) JP2016510795A (cg-RX-API-DMAC7.html)
KR (2) KR20210099201A (cg-RX-API-DMAC7.html)
CN (2) CN105188706A (cg-RX-API-DMAC7.html)
AU (2) AU2014230096C1 (cg-RX-API-DMAC7.html)
BR (1) BR112015020209A2 (cg-RX-API-DMAC7.html)
CA (1) CA2903577C (cg-RX-API-DMAC7.html)
CL (1) CL2015002369A1 (cg-RX-API-DMAC7.html)
EA (1) EA037712B1 (cg-RX-API-DMAC7.html)
IL (1) IL240064A0 (cg-RX-API-DMAC7.html)
MX (2) MX2015011466A (cg-RX-API-DMAC7.html)
PH (1) PH12015502042A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014140284A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
NZ600394A (en) 2006-05-04 2014-04-30 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
CN107961377B (zh) 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
CN109152840A (zh) * 2016-03-28 2019-01-04 英特塞普特医药品公司 通过结合fxr激动剂和arb获得的药物
CA3022202A1 (en) * 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
EP3823624A1 (en) * 2018-07-17 2021-05-26 Boehringer Ingelheim International GmbH Cardiosafe antidiabetic therapy
AU2019306036B2 (en) * 2018-07-17 2025-05-15 Boehringer Ingelheim International Gmbh Cardio- and renosafe antidiabetic therapy
EP3901146A4 (en) * 2018-12-18 2022-01-19 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company PHENYLPYRROLIDINE COMPOUND AND USE THEREOF
WO2022244846A1 (ja) * 2021-05-19 2022-11-24 Kagami株式会社 細胞増殖の調整のための組成物及び細胞増殖の調整方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064352A1 (en) * 2009-11-27 2011-06-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2012065993A1 (en) * 2010-11-15 2012-05-24 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013171167A1 (en) * 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174768A1 (en) * 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
TW225528B (cg-RX-API-DMAC7.html) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
MXPA03007349A (es) 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
HRP20050157B1 (en) 2002-08-21 2013-01-31 Boehringer Ingelheim Pharma 8-[3-amino-piperidin-1-yl]-xanthines,the production thereof and the use of the same as medicaments
DE10238477A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238470A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10251927A1 (de) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
UY28103A1 (es) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
DE10327439A1 (de) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE10359098A1 (de) 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
RS50982B (sr) 2004-02-18 2010-10-31 Boehringer Ingelheim International Gmbh. 8-[3-amino piperidin-1-il]-ksantini, njihovo dobijanje i njihova primena kao dpp-iv inhibitora
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
WO2005097798A1 (de) 2004-04-10 2005-10-20 Boehringer Ingelheim International Gmbh Neue 2-amino-imidazo[4,5-d]pyridazin-4-one und 2-amino-imidazo[4,5-c]pyridin-4-one, deren herstellung und deren verwendung als arzneimittel
DE102004022970A1 (de) 2004-05-10 2005-12-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazolderivate, deren Herstellung und deren Verwendung als Intermediate zur Herstellung von Arzneimitteln und Pestiziden
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2006041976A1 (en) 2004-10-08 2006-04-20 Novartis Ag Combination of organic compounds
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
BRPI0518651A2 (pt) 2004-12-24 2008-12-02 Dainippon Sumitomo Pharma composto, uma prà-droga do mesmo, ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, composiÇço farmacÊutica, inibidor de dipeptidil peptidase iv, uso de um composto, uma prà-droga do mesmo ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, e, mÉtodo para tratar diabetes
JP4568361B2 (ja) * 2005-04-22 2010-10-27 アラントス・ファーマシューティカルズ・ホールディング・インコーポレーテッド ジペプチジルペプチダーゼ−ｉｖ阻害剤
JP5112307B2 (ja) 2005-07-01 2013-01-09 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｅｔｐ阻害剤を合成するための方法
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1966215A1 (en) 2005-12-23 2008-09-10 Novartis AG Condensed heterocyclic compounds useful as dpp-iv inhibitors
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
NZ600394A (en) 2006-05-04 2014-04-30 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
EP2057160A1 (en) 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
UY32177A (es) * 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
JP2012522015A (ja) * 2009-03-27 2012-09-20 ブリストル−マイヤーズ スクイブ カンパニー Ｄｐｐ−ｉｖ阻害剤を用いて主要有害心血管事象を予防する方法
WO2011039367A2 (en) * 2009-10-02 2011-04-07 Boehringer Ingelheim International Gmbh Therapeutic uses of pharmaceutical compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064352A1 (en) * 2009-11-27 2011-06-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2012065993A1 (en) * 2010-11-15 2012-05-24 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013171167A1 (en) * 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174768A1 (en) * 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BERTHOLD HOCHER ET AL, "Renal and Cardiac Effects of DPP-4 Inhibitors - from Preclinical Development to Clinical Research", KIDNEY AND BLOOD PRESSURE RESEARCH, CH, (2012-02-01), vol. 36, no. 1, pages 65 - 84 *
Chaykovska et al., Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy, PLoS One, Nov. 2011, Vol. 6, Issue 11, pp. 1-9, e27861 *
Groop et al., Effects of DPP-4 inhibitor linagliptin on albuminuria in patients with type 2 diabetes and diabetic nephropathy, Abstract, 48th EASD Annual Meeting, Berlin, Abstract 36, October 2012 *
Heise et al, Treatment with BI 1356, a Novel and Potent DPP-IV Inhibitor, Significantly Reduces Glucose Excursions after an oGTT in Patients with Type 2 Diabetes, Poster Abstract 588-P, Diabetes Abstract Book, 67th Scientific Sessions, 2007 *
Isomaa et al., Cardiovascular Morbidity and Mortality Associated with Metabolic Syndrome, Diabetes Care, Vol. 24, No. 4, April 2001, pp 683-689 (Isomaa, previously cited and supplied) *
MARIA ANGELA SORTINO ET AL, "Linagliptin: A thorough Characterization beyond Its Clinical Efficacy", FRONTIERS IN ENDOCRINOLOGY, CH, (2013-02-26), vol. 4, doi:10.3389/fendo.2013.00016, ISSN 1664-2392, pages 16 - 1 *
ODD ERIK JOHANSEN ET AL, "Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme", CARDIOVASCULAR DIABETOLOGY, vol. 11, no. 1, P3 *
Yamagishi and Matsui, Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes, Curr. Pharm. Design, 2012, 17, 4379-4385 (Yamagishi (first available online 12/2011) *

Also Published As

Publication number Publication date
AU2019203445A1 (en) 2019-06-06
KR20210099201A (ko) 2021-08-11
KR20150128726A (ko) 2015-11-18
EA037712B1 (ru) 2021-05-13
EP3409279A1 (en) 2018-12-05
US20210205316A1 (en) 2021-07-08
MX2015011466A (es) 2016-01-22
PH12015502042B1 (en) 2016-01-18
US20250025470A1 (en) 2025-01-23
EP4364796A2 (en) 2024-05-08
US20200338086A1 (en) 2020-10-29
CL2015002369A1 (es) 2016-02-19
BR112015020209A2 (pt) 2017-07-18
CN110075098A (zh) 2019-08-02
MX2021014242A (es) 2022-01-06
US20240033270A1 (en) 2024-02-01
IL240064A0 (en) 2015-09-24
PH12015502042A1 (en) 2016-01-18
CA2903577A1 (en) 2014-09-18
US20180263990A1 (en) 2018-09-20
EP4364796A3 (en) 2024-07-24
AU2014230096A1 (en) 2015-08-06
JP2016510795A (ja) 2016-04-11
JP2025115998A (ja) 2025-08-07
EP2968344A1 (en) 2016-01-20
EA201500934A1 (ru) 2016-03-31
US20190192523A1 (en) 2019-06-27
JP2019112409A (ja) 2019-07-11
EP3744327A1 (en) 2020-12-02
CA2903577C (en) 2023-10-17
US20160089373A1 (en) 2016-03-31
WO2014140284A1 (en) 2014-09-18
CN105188706A (zh) 2015-12-23
US20170065596A1 (en) 2017-03-09
AU2014230096B2 (en) 2019-02-21
NZ710249A (en) 2021-04-30
JP2021095409A (ja) 2021-06-24
US20140274889A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
US20250025470A1 (en) Cardio- and renoprotective antidiabetic therapy
US20240299399A1 (en) Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
AU2011331247B2 (en) Vasoprotective and cardioprotective antidiabetic therapy
WO2013174768A1 (en) A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
AU2017272209B2 (en) Vasoprotective and cardioprotective antidiabetic therapy
AU2013204252B2 (en) Vasoprotective and cardioprotective antidiabetic therapy
NZ710249B2 (en) Use of linagliptin in cardio- and renoprotective antidiabetic therapy

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 MAY 2019

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 15 MAY 2019

FGA Letters patent sealed or granted (standard patent)